Clinical Trial Update: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Umbralisib plus Ublituximab (U2) in progressive chronic lymphocytic leukemia after novel therapy was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Chronic Lymphocytic Leukemia, CLL Progression | Phase 2 | Status: TERMINATED | Results posted: 2023-06-15